Craig A. Tooman - Jan 2, 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)

Role: President and CEO, Director
Signature: /s/ Rhonda Hellums, Attorney-in-Fact
Stock symbol: SLN
Transactions as of: Jan 2, 2025
Transactions value $: $0
Form type: 3
Date filed: 1/2/2025, 04:39 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SLN	Ordinary Shares						33.5K	Jan 2, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SLN	Employee Share Option (Right to Buy)							Jan 2, 2025	Ordinary Shares	580K	$7.02	Direct	F1
holding	SLN	Employee Share Option (Right to Buy)							Jan 2, 2025	Ordinary Shares	265K	$7.87	Direct	F2
holding	SLN	Employee Share Option (Right to Buy)							Jan 2, 2025	Ordinary Shares	375K	$6.33	Direct	F3
holding	SLN	Employee Share Option (Right to Buy)							Jan 2, 2025	Ordinary Shares	900K	$3.86	Direct	F4
holding	SLN	Employee Share Option (Right to Buy)							Jan 2, 2025	Ordinary Shares	2.1M	$5.13	Direct	F5
holding	SLN	Employee Share Option (Right to Buy)							Jan 2, 2025	Ordinary Shares	217K	$3.33	Direct	F6
holding	SLN	Employee Share Option (Right to Buy)							Jan 2, 2025	Ordinary Shares	651K	$5.90	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One fourth (1/4th) of the shares subject to the option award vested on January 6, 2022, and one twelfth (1/12th) of the remaining shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F2	This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F3	This option vested or shall vest in equal monthly installments over a four-year period measured from one month following February 21, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F4	This option vested or shall vest in equal monthly installments over a five-year period measured from one month following September 16, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F5	This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 5, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F6	One fourth (1/4th) of the shares subject to the option vested on September 14, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.
F7	One fourth (1/4th) of the shares subject to the option shall vest on January 4, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.